ANNX is expected to report earnings to rise 7.32% to -26 cents per share on March 20
Q4'24
Est.
$-0.27
Q3'24
Beat
by $0.01
Q2'24
Est.
$-0.23
Q1'24
Beat
by $0.13
Q4'23
Beat
by $0.09
The last earnings report on November 14 showed earnings per share of -25 cents, beating the estimate of -25 cents. With 151.48K shares outstanding, the current market capitalization sits at 560.68M.
a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain